Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study

Okosieme, Onyebuchi, Usman, Danyal, Taylor, Peter N. ORCID: https://orcid.org/0000-0002-3436-422X, Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462, Lyons, Greta, Moran, Carla, Chatterjee, Krishna and Rees, Dafydd Aled ORCID: https://orcid.org/0000-0002-1165-9092 2023. Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study. The Lancet Diabetes & Endocrinology 11 (9) , pp. 657-666. 10.1016/S2213-8587(23)00155-9 Item availability restricted.

	PDF - Supplemental Material Restricted to Repository staff only until 17 January 2024 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (445kB)
	PDF - Accepted Post-Print Version Restricted to Repository staff only until 17 January 2024 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (368kB)

Abstract

Background Individuals with resistance to thyroid hormone owing to mutations in the thyroid hormone receptor β gene (RTHβ) exhibit impaired tissue sensitivity to thyroid hormones, but retain sensitivity in cardiac tissue. Long-term health and survival outcomes in this rare disorder have not been evaluated. We investigated all-cause mortality and cardiovascular event risk in a cohort of patients with RTHβ, followed-up in UK endocrine clinics. Methods In a retrospective cohort design, we linked genetically confirmed patients with RTHβ and age-matched and sex-matched population controls to outcomes in datasets within the Welsh Secure Anonymised Information Linkage (SAIL) Databank. Kaplan-Meier and Cox regression models analysed associations of RTHβ with all-cause mortality and cardiovascular events. Findings We identified 61 patients with a genetic diagnosis of RTHβ between Jan 1, 1997, and Dec 31, 2019, and matched them with 2750 controls. Compared with controls, patients exhibited increased risks for all-cause mortality (hazard ratio [HR] 2·84, 95% CI 1·59–5·08), atrial fibrillation (10·56, 4·72–23·63), heart failure (HR 6·35, 95% CI 2·26–17·86), and major adverse cardiovascular events (MACE), comprising cardiovascular death, acute myocardial infarction, heart failure, or strokes (HR 3·49, 95% CI 2·04–5·99). The median age of first occurrence of any adverse event was 11 years earlier in patients (56 years, 95% CI 44–65) compared with controls (67 years, 65–70). Cubic spline analyses showed positive associations between FT4 concentrations at diagnosis and mortality or MACE, with FT4 concentration of 30 pmol/L or greater conferring increased risk. Compared with no intervention, treatment with antithyroid drugs, surgery or radioiodine gland ablation, or thyroxine did not control thyroid hormone excess. Interpretation We have documented reduced survival and increased cardiovascular morbidity in a cohort of patients with RTHβ for the first time. These outcomes might be driven by lifelong cardiac exposure to thyroid hormone excess; and effective therapies, targeting hormone resistant pathways, could potentially curtail this risk.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Elsevier
ISSN:	2213-8587
Date of First Compliant Deposit:	5 June 2023
Date of Acceptance:	21 May 2023
Last Modified:	09 Dec 2023 23:16
URI:	https://orca.cardiff.ac.uk/id/eprint/160176

Actions (repository staff only)

Edit Item